In addition, AGO2 confers resistance to viral replication and could be a therapeutic candidate for viral infection [32] and our data showed that the expression of AGO2 was higher in the LDGs than the NDGs and the expression of AGO2 was down‐regulated by the incubation with SARS‐CoV‐2 in LDGs. Here, AGO2 is linked to viral infectious disease.